Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its holdings in Glaukos Co. (NYSE:GKOS) by 3.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 381,288 shares of the medical instruments supplier’s stock after selling 11,822 shares during the quarter. New York State Common Retirement Fund owned about 0.69% of Glaukos worth $57,170,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in shares of Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. State Street Corp boosted its position in shares of Glaukos by 5.3% in the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after purchasing an additional 98,109 shares in the last quarter. Primecap Management Co. CA boosted its position in shares of Glaukos by 2.0% in the 3rd quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Glaukos by 6.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in shares of Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier’s stock worth $87,776,000 after purchasing an additional 119,527 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of Glaukos stock opened at $161.30 on Thursday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The business has a 50-day moving average price of $152.65 and a 200 day moving average price of $139.03. The firm has a market cap of $8.89 billion, a PE ratio of -53.41 and a beta of 1.04.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,744 shares of company stock worth $2,792,151 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on GKOS. JPMorgan Chase & Co. lifted their price target on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Wells Fargo & Company lifted their price target on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $140.00 to $200.00 in a research report on Wednesday. Finally, BTIG Research lifted their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $159.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.